Last reviewed · How we verify

NCT06557616: CoolCryo

Safety and Efficacy of the CoolCryo System for Cardiac Cryoablation in the Treatment of Atrial Fibrillation

Recruiting now Last updated 23 September 2025
What this trial tests

trial in Atrial Fibrillation, Paroxysmal or Persistent in 20 participants. Currently enrolling.

Timeline
3 July 2024
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorMedinice S.A.
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment20
Start date3 July 2024
Primary completion30 June 2026
Estimated completion30 June 2026
Sites2 locations across Poland

Conditions studied

Sponsor

Medinice S.A.

Who can join

18 and older, any sex, with Atrial Fibrillation, Paroxysmal or Persistent or Mitral Valve Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study involves endocardial cryoablation of the left and/or right atrium of the heart using the CoolCryo system as an adjunct to mitral valve surgery, with the aim of eliminating atrial fibrillation (AF), which is a common sequelae of mitral valve defects and is associated with an increased risk of ischaemic stroke, heart failure and death.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Medinice S.A. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06557616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing